The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 23, 2023

Filed:

Feb. 22, 2021
Applicant:

G1 Therapeutics, Inc., Research Triangle Park, NC (US);

Inventors:

Jay Copeland Strum, Hillsborough, NC (US);

John Emerson Bisi, Chapel Hill, NC (US);

Patrick Joseph Roberts, Durham, NC (US);

Francis X. Tavares, Durham, NC (US);

Assignee:

G1 Therapeutics, Inc., Research Triangle Park, NC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/527 (2006.01); C07D 487/14 (2006.01); A61K 45/06 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61P 35/04 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 31/555 (2006.01); A61K 31/7048 (2006.01);
U.S. Cl.
CPC ...
A61K 31/527 (2013.01); A61K 9/0053 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/555 (2013.01); A61K 31/7048 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07D 487/14 (2013.01);
Abstract

This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.


Find Patent Forward Citations

Loading…